NEULAND LABORATORIES
Quarterly Results Analysis [Sep2024]
NEULAND LABORATORIES Quarterly Results
Consolidated | Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 Audited |
Jun2023 UnAudited |
Mar2023 Audited |
Dec2022 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹311 Cr | ₹440 Cr | ₹385 Cr | ₹393 Cr | ₹418 Cr | ₹363 Cr | ₹407 Cr | ₹269 Cr |
Expenses | ₹249 Cr | ₹316 Cr | ₹278 Cr | ₹272 Cr | ₹280 Cr | ₹266 Cr | ₹287 Cr | ₹215 Cr |
Operating Income | ₹62 Cr | ₹123 Cr | ₹107 Cr | ₹121 Cr | ₹137 Cr | ₹97 Cr | ₹120 Cr | ₹54 Cr |
Other Income | ₹4 Cr | ₹5 Cr | ₹5 Cr | ₹2 Cr | ₹3 Cr | ₹2 Cr | ₹8 Cr | ₹1 Cr |
Interest | ₹1 Cr | ₹3 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹2 Cr | ₹4 Cr | ₹3 Cr |
Depreciation | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹15 Cr | ₹15 Cr | ₹14 Cr | ₹13 Cr | ₹13 Cr |
Profit Before Tax | ₹49 Cr | ₹130 Cr | ₹92 Cr | ₹104 Cr | ₹122 Cr | ₹83 Cr | ₹110 Cr | ₹39 Cr |
Profit After Tax | ₹33 Cr | ₹98 Cr | ₹68 Cr | ₹81 Cr | ₹89 Cr | ₹62 Cr | ₹85 Cr | ₹31 Cr |
EPS | ₹25.46 | ₹75.86 | ₹52.37 | ₹63.09 | ₹69.18 | ₹47.96 | ₹65.53 | ₹23.68 |
Industry Peers & Returns | 1W | 1M | 1Y |
NEULAND LABORATORIES | -3% | 5.6% | 183.5% |
SUN PHARMACEUTICAL INDUSTRIES | -1.4% | -7.1% | 48% |
CIPLA | -3.5% | -5.2% | 18% |
DR REDDYS LABORATORIES | -3.9% | -10.1% | 10.1% |
ZYDUS LIFESCIENCES | -0.3% | -7.3% | 52.2% |
DIVIS LABORATORIES | 1.5% | -2.1% | 63% |
MANKIND PHARMA | -2.3% | -3% | 39.6% |
TORRENT PHARMACEUTICALS | -1.8% | -10.2% | 51.3% |
LUPIN | -2.4% | -6.4% | 73.9% |
NEULAND LABORATORIES Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | -29.29 % |
Y-o-Y | -25.59 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Sep2024 | ₹311 Cr | -29.29 | |
Jun2024 | ₹440 Cr | 14.18 | |
Mar2024 | ₹385 Cr | -1.99 | |
Dec2023 | ₹393 Cr | -5.97 | |
Sep2023 | ₹418 Cr | 15.08 | |
Jun2023 | ₹363 Cr | -10.83 | |
Mar2023 | ₹407 Cr | 51.19 | |
Dec2022 | ₹269 Cr | - |
NEULAND LABORATORIES Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | -49.56 % |
Y-o-Y | -54.74 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Sep2024 | ₹62 Cr | -49.56 | |
Jun2024 | ₹123 Cr | 15.38 | |
Mar2024 | ₹107 Cr | -11.83 | |
Dec2023 | ₹121 Cr | -11.80 | |
Sep2023 | ₹137 Cr | 41.86 | |
Jun2023 | ₹97 Cr | -19.14 | |
Mar2023 | ₹120 Cr | 121.62 | |
Dec2022 | ₹54 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | -28.65 % |
Y-o-Y | -39.17 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Sep2024 | 20.02% | -28.65 | |
Jun2024 | 28.06% | 1.04 | |
Mar2024 | 27.77% | -10.04 | |
Dec2023 | 30.87% | -6.20 | |
Sep2023 | 32.91% | 23.26 | |
Jun2023 | 26.7% | -9.31 | |
Mar2023 | 29.44% | 46.54 | |
Dec2022 | 20.09% | - |
NEULAND LABORATORIES Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | -66.44 % |
Y-o-Y | -63.20 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Sep2024 | ₹33 Cr | -66.44 | |
Jun2024 | ₹98 Cr | 44.86 | |
Mar2024 | ₹68 Cr | -16.99 | |
Dec2023 | ₹81 Cr | -8.80 | |
Sep2023 | ₹89 Cr | 44.23 | |
Jun2023 | ₹62 Cr | -26.81 | |
Mar2023 | ₹85 Cr | 176.76 | |
Dec2022 | ₹31 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | -52.52 % |
Y-o-Y | -50.51 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Sep2024 | 10.57 % | -52.52 | |
Jun2024 | 22.26 % | 26.84 | |
Mar2024 | 17.55 % | -15.30 | |
Dec2023 | 20.72 % | -3.00 | |
Sep2023 | 21.36 % | 25.28 | |
Jun2023 | 17.05 % | -17.91 | |
Mar2023 | 20.77 % | 83.00 | |
Dec2022 | 11.35 % | - |
NEULAND LABORATORIES Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | -66.44 % |
Y-o-Y | -63.20 % |
Quarters | EPS | % Change | |
---|---|---|---|
Sep2024 | ₹25.46 | -66.44 | |
Jun2024 | ₹75.86 | 44.85 | |
Mar2024 | ₹52.37 | -16.99 | |
Dec2023 | ₹63.09 | -8.80 | |
Sep2023 | ₹69.18 | 44.25 | |
Jun2023 | ₹47.96 | -26.81 | |
Mar2023 | ₹65.53 | 176.73 | |
Dec2022 | ₹23.68 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD